TWI762602B - Solid medicine container and water treatment method - Google Patents

Abstract

A solid medicament container, which is filled with water-soluble solid medicament inside a container, and in the solid medicament container, the container has a container space that can accommodate a plurality of water-soluble solid medicaments, and allows water to be treated to flow into the container The inflow port of the space and the outflow port that makes the water to be treated flow out of the storage space, in the storage space, a part or all of the water-soluble solid medicine is laminated in the vertical direction through the water-soluble film, and the water-soluble solid medicine is laminated in the vertical direction. At least a part of the membrane is arranged above the inflow port and the outflow port.

Description

Solid medicine container and water treatment method

The present invention relates to a solid medicine container containing a water-soluble solid medicine, and specifically, to a solid medicine container having the following functions and a water treatment method using the solid medicine container for water treatment, The function is to continuously release the active ingredient into the water to be treated while gradually dissolving the water-soluble solid drug by contact with the water to be treated.

As a technique for gradually dissolving a water-soluble solid drug (hereinafter, referred to as a water-soluble solid drug) with respect to the water to be treated, while continuously releasing its active ingredient, the following technology is disclosed. The solid-medicine dissolving device is constituted by the body, and the inner cylinder is rotated to change the degree of overlapping of the communication holes formed in the inner cylinder and the outer cylinder, respectively, so that the amount of the water to be treated flowing into the inner cylinder is affected. Adjustment is performed to adjust the dissolution rate of the water-soluble solid drug filled into the inner cylinder (Patent Document 1).

[Prior Art Literature]

[Patent Literature]

[Patent Document 1] Utility Model Registration No. 3173540

However, in order to use the technology described in Patent Document 1 to treat water-soluble solid pharmaceuticals It is necessary to adjust the amount of the treated water flowing into the inner cylinder by manually rotating the inner cylinder every time according to the fluctuation of the flow rate or flow rate of the water to be treated, and the operation is cumbersome. .

An object of the present invention made to solve the above-mentioned problems is to provide a solid medicine container which can continuously release the active ingredient of the water-soluble solid medicine for a long period of time, and which can easily adjust the dissolution rate of the water-soluble solid medicine.

The inventors of the present invention have found that the dissolution rate of the water-soluble solid drug can be easily adjusted by laminating the water-soluble solid drug in the vertical direction through a water-soluble film in the interior of the container, and it can be sustained for a long period of time. Release the active ingredient of a water-soluble solid dosage form.

The present invention has been completed based on the above findings, and provides the following [1] to [7].

[1] A solid medicament container, which is filled with a water-soluble solid medicament inside a container, wherein, in the solid medicament container, the container has a accommodating space capable of accommodating a plurality of water-soluble solid medicaments, and allows water to be treated. The inflow port that flows into the storage space and the outflow port that makes the water to be treated flow out of the storage space. In the storage space, a part or all of the water-soluble solid medicine is layered in the vertical direction through the water-soluble film, and the At least a part of the water-soluble film is arranged above the inflow port and the outflow port.

[2] The solid drug container according to the above [1], wherein the water-soluble film is a packaging material for packaging the water-soluble solid drug.

[3] The solid drug container according to the above [1] or [2], wherein the water-soluble The flexible film is formed by film-forming a raw material containing a polyvinyl alcohol-based resin.

[4] The solid drug container according to any one of the above [1] to [3], wherein the dissolution time of the water-soluble film in water at 23° C. is 8 seconds or more and 99 seconds or less.

[5] A water treatment method, which performs water treatment using a solid drug storage body having a storage space capable of storing a plurality of water-soluble solid drugs, an inflow port through which water to be treated flows into the storage space, and a The outflow port through which the water to be treated flows out from the storage space, and the storage space is filled with water-soluble solid pharmaceuticals, and in the water treatment method, a part or all of the multiple water-soluble solid pharmaceuticals are separated from the water-soluble film. Water treatment is performed by stacking layers in the vertical direction and arranging at least a part of the water-soluble film above the inflow port and the outflow port.

[6] The water treatment method according to the above [5], wherein when the water-soluble solid chemical disposed below the inflow port and the outflow port is dissolved, the water-soluble solid chemical disposed in the inflow port and the outflow port The water-soluble film above the outflow port is partially dissolved, and the remaining part of the partially dissolved water-soluble film prevents the contact between the water-soluble solid chemical disposed on the remaining part and the water to be treated.

[7] The water treatment method according to the above [6], wherein the remaining portion obstructs the horizontal cross section of the storage space.

In the solid medicine container of the present invention, among the plurality of water-soluble solid medicines stored in the storage container, the medicines that are not exposed to the water to be treated flowing through the flow path formed between the inflow port and the outflow port of the storage container, that is, , which is disposed above the drug that is gradually dissolved by exposure to the treated water flowing through the flow path and is the drug on the water-soluble film Even in the process of gradually dissolving the agent directly under it, the presence of the water-soluble film prevents contact with the water to be treated, thereby reducing wetting. Therefore, the water content of the water-soluble solid drug can be reduced and the residual ratio of the active ingredient of the drug can be increased compared with the case of the configuration under the same conditions except that the water-soluble film is present.

Therefore, according to the present invention, the active ingredient of the water-soluble solid medicine can be continuously released for a long period of time, and the dissolution rate of the water-soluble solid medicine can be easily adjusted.

10: Storage container

11: Container body

11a: Upper member

11b: Lower member

12: Divide the Wall

13: Containment space

14: Non-Containment Space

15a, 15b, 15c: container communication paths

16: Divide the wall connection path

17: Water-soluble film

S1, S2, S3: water-soluble solid pharmaceuticals

FIG. 1 is a perspective view showing the outline of a container according to an embodiment of a solid drug container.

FIG. 2 is a vertical cross-sectional view of the solid medicine container shown in FIG. 1 .

3 is a vertical cross-sectional view of the solid medicine container for explaining the first embodiment of the method of using the solid medicine container.

4 is a schematic explanatory diagram of a method of using the solid drug container.

5 is a vertical cross-sectional view of a solid drug container for explaining a second embodiment of a method of using the solid drug container.

Hereinafter, the present invention will be described in detail.

The solid medicine container of the present invention is filled with a water-soluble solid medicine inside a container, and in the solid medicine container, the container has a storage space that can store a plurality of water-soluble solid medicines, and the water to be treated flows into the container. The inflow port of the space and the outflow port through which the treated water flows out of the storage space, in the storage space Among them, a part or all of the water-soluble solid drug is laminated in the vertical direction through a water-soluble film, and at least a part of the water-soluble film is arranged above the inflow port and the outflow port.

By accommodating and using the water-soluble solid medicine in the solid medicine container with the above configuration, the active ingredient of the water-soluble solid medicine can be continuously released for a long period of time, and the dissolution rate of the water-soluble solid medicine can be easily adjusted.

In the present embodiment, a description will be given of a solid drug storage body filled with a water-soluble solid drug used for water treatment of cooling water of a cooling tower.

[storage container]

The storage container has, in the lower part of the container, an inflow port through which the water to be treated flows into the container, and an outflow port through which the water to be treated that has flowed into the container flows out of the container. For example, the storage container has a cylindrical portion, an upper surface portion and a lower surface portion that seal both ends of the cylindrical portion, an inflow port provided in the cylindrical portion and/or the lower surface portion, and an inflow port provided in the cylindrical portion and/or Outflow opening of the lower part. Furthermore, the inflow port may also serve as the outflow port.

For example, as shown in FIG. 1 , a storage container 10 having a substantially cylindrical container body 11 can be used. As shown in FIG. 2 , a substantially cylindrical partition wall 12 is provided inside the container body 11 , and the interior of the container body 11 is divided by the partition wall 12 into an accommodation space 13 for accommodating the water-soluble solid drug S1 and a non-accommodating space 13 . The non-accommodating space 14 of the water-soluble solid medicine.

The partition wall 12 has an opening in the lower part.

(container body 11)

The container body 11 includes an upper member 11a and a lower member 11b.

The upper member 11a and the lower member 11b are fitted to form the container body 11 .

By adopting a structure in which the container body can be divided and can be easily integrated, it is possible to easily perform the operation of re-accommodating or additionally replenishing the water-soluble solid drug in the accommodating space.

The shape or size of the container body is not particularly limited as long as it can accommodate a water-soluble solid drug. The shape and size of the container body can be appropriately set from the viewpoints of the size of the cooling tower, the ease of transportation and handling of the container, and the like.

The shape of the container body can be, for example, a circular, elliptical, or polygonal cylindrical body in cross section, or a shape in which the outer surface is rounded as a whole.

From the viewpoint of the easiness of handling the container body, the size of the container body is preferably set to a level that can be lifted with one hand.

The top of the upper member 11a, the vicinity of the bottom of the side peripheral portion of the lower member 11b, and the bottom of the lower member 11b have a container communication path 15a, a container communication path 15b, and a container communication path 15c.

The cooling water flows between the outside of the container body 11 and the non-accommodating space 14 via the container communication path 15a, the container communication path 15b, and the container communication path 15c.

The container communication path 15a, container communication path 15b, and container communication path 15c are not particularly limited in shape, size, arrangement, and number as long as cooling water can flow, and can be appropriately set according to the desired flow rate of cooling water. The shape of the container communication path 15a, the container communication path 15b, and the container communication path 15c can be, for example, a circular hole shape, a square hole shape, a slit shape, a mesh shape, or the like. The container communication path 15a is arranged in a non- Above the accommodating space 14, the non-accommodating space 14 communicates with the outside of the accommodating container 10 through the container communication path 15a.

(dividing wall 12)

The partition wall 12 has a cylindrical shape, and is vertically provided from the top inner wall of the upper member 11a. In the container body 11 in which the upper member 11 a and the lower member 11 b are fitted, the space inside the partition wall 12 is the storage space 13 , and the outer space is the non-receiving space 14 .

The shape, size, and arrangement of the partition wall 12 are set so as to facilitate the operation of re-accommodating or additionally replenishing the water-soluble solid drug into the containing space.

Specifically, the shape, size, and arrangement of the partition wall 12 are set so that the accommodation space 13 on the inner side of the partition wall 12 has a size sufficient for the above-mentioned operation.

The partition wall 12 is arrange|positioned so that it may not contact the bottom surface of the lower member 11b. A gap between the lower end of the partition wall 12 and the bottom surface of the lower member 11 b facing the partition wall becomes the partition wall communication path 16 .

The cooling water circulates between the accommodation space 13 and the non-accommodating space 14 via the partition wall communication path 16 .

In the present embodiment, the partition wall communication path 16 functions as an "inflow port" and a "outflow port", and the container communication path 15b and the container communication path 15c function as an "outflow port".

In addition, the shape, size, arrangement, and number of the dividing wall communication path 16 are not particularly limited as long as the cooling water can flow therethrough, and can be determined according to the needs of the cooling water. flow to be set appropriately. As a shape, a round hole shape, a square hole shape, a slit shape, a mesh shape, etc. can be used, for example. In addition, when the dividing wall is cylindrical, the lower end of the dividing wall is in contact with the bottom surface of the container body facing it, and at least a part of the dividing wall and the bottom surface of the container body may have a gap. form to form a dividing wall communication path.

Among them, in the case where the water level of the cooling water flowing into the non-accommodating space is low, from the viewpoint of more reliable circulation of the cooling water between the containing space and the non-accommodating space, the partition wall communication path is preferably at least one extends to the bottom surface of the container body.

The storage container 10 of the present embodiment is made of translucent polypropylene.

From the viewpoint that the state of the water-soluble solid medicine inside the container can be easily visually observed from the outside of the container, the container body and the partition wall preferably have transparency. In addition, since it is used in a cooling tower, it is preferable to be made of plastic from the viewpoints of ease of handling and water resistance.

[Water-soluble solid drug]

The water-soluble solid chemical is not particularly limited, and for example, in addition to the solid chemical as a water treatment agent for cooling water of a cooling tower, a solid chemical as a water treatment agent for wastewater may be exemplified.

The water-soluble solid chemical used as a water treatment agent for cooling water of a cooling tower is not particularly limited, and a halogen-based oxidizing agent, an organic-based bactericide, and the like can be exemplified. Furthermore, when a halogen-based oxidizing agent and an organic-based bactericide are used in combination and the organic-based bactericide and the halogen-based oxidizing agent are reactive, from the viewpoint of preventing premature reaction of the two agents, it is preferable to use Halogen-based oxidant as an active ingredient of solid pharmaceutical (A) and organic The solid medicine (B) in which the bactericide is an active ingredient is accommodated in each container.

(Solid Medicine (A))

The solid agent (A) with the halogen-based oxidizing agent as an active ingredient plays the role of sterilizing and sterilizing or inhibiting stickiness in the water treatment agent. As the halogen-based oxidizing agent, halogenated hydantoin-based compounds, isocyanuric acid-based compounds, and the like can be exemplified.

The halogenated hydantoin-based compound is a solid organic halogen-based oxidizing agent, and when it comes into contact with water, it releases active halogen having a strong oxidizing power.

From the viewpoint of solubility in water, etc., it is preferable in that the active halogen is continuously released for a long period of time. As for the halogen-based oxidizing agents marketed as sustained-release tablets, in addition to halogenated hydantoin-based compounds, there are also calcium hypochlorite, sodium chlorite, dichloroisocyanuric acid, trichloroisotrimer Cyanic acid etc. are the active ingredients. The inventors of the present invention found that among these halogenated oxidizing agents, the dissolution rate of the halogenated hydantoin-based compound as an active ingredient was relatively small. According to this knowledge, the halogenated hydantoin-based compound can be said to be the best from the viewpoint of continuing the excellent chemical effect caused by the combined use with the solid chemical containing the organic biocide. Furthermore, when the halogenated hydantoin-based compound is brought into contact with water, relatively few odors are generated, so it is also preferable from the viewpoint of safety at the time of handling.

Specific examples of the halogenated hydantoin-based compounds include 1-bromo-3-chloro-5,5-dimethylhydantoin (hereinafter, abbreviated as BCDMH (1-bromo-3-chloro- 5,5-dimethylhydantoin)), 1,3-dichloro-5,5-dimethylhydantoin, 1,3-dibromo-5,5-dimethylhydantoin, 1-bromo- 3-Chloro-5,5-diethylhydantoide, 1,3-dichloro-5,5-diethylhydantoide, 1-bromo-3-chloro-5-methyl-5- Ethyl Ethyl urea, etc. These may be used individually by 1 type, and may use 2 or more types together. Among these, BCDMH and 1,3-dichloro-5,5-dimethyl are preferred from the viewpoints of the balance between the dissolution rate at the time of contact with water and the dissolution rate of the solid drug (B) or the ease of acquisition. Ethyl hydantoin.

The form of the halogen-based oxidizing agent as described above is preferably a lozenge. The manufacturing method of a tablet is not specifically limited, It can manufacture by a well-known method. Usually, it is produced by press molding using additives such as excipients and binders. The dissolution rate of the tablet in the water to be treated can be adjusted by adjusting the type or addition amount of the excipient or the binding agent.

As a tablet, a commercial item can also be used.

From the viewpoint of elution of the halogen-based oxidizing agent at a moderate elution rate, when all the available halogen components are regarded as available chlorine, the content of the halogen-based oxidizing agent in the solid drug (A) is calculated in terms of available chlorine (Cl2) conversion. It is preferably 10% by mass or more, more preferably 30% by mass to 90% by mass, and still more preferably 40% by mass to 70% by mass.

From the viewpoint of the bactericidal action against bacteria of the genus Legionella, the concentration of available halogen (Cl2 conversion) in the water to be treated by the solid chemical (A) is preferably 0.1 mg/L or more, more preferably 0.1 mg/L to 5 mg/L, more preferably 0.1 mg/L to 2 mg/L.

(Solid Medicine (B))

A synergistic effect of the bactericidal action can be obtained by using the solid drug (B) containing the organic-based bactericide having reactivity with the halogen-based oxidizing agent in combination with the solid drug (A).

The organic-based bactericide has reactivity with the halogen-based oxidizing agent. Since toxic halogen-based substances such as chlorine gas are generated by the reaction with the halogen-based oxidizing agent, it is difficult to mix and integrate with the halogen-based oxidizing agent. Therefore, when formulating an organic bactericide, it is necessary to prepare an agent independent of the halogen-based oxidizing agent. Therefore, in the present embodiment, the solid drug (B) is prepared separately from the solid drug (A).

As an active ingredient in the organic-based sterilizer, it is preferable to contain an isothiazoline-based compound from the viewpoint of the sterilization performance by combined use with a halogen-based oxidizing agent.

Specific examples of the isothiazoline-based compound include 5-chloro-2-methyl-4-isothiazolin-3-one (hereinafter abbreviated as Cl-MIT), 2-methyl-4-iso Thiazolin-3-one, 4,5-dichloro-2-methyl-4-isothiazolin-3-one, 2-ethyl-4-isothiazolin-3-one, 2-n-octyl- 4-isothiazolin-3-one, 5-chloro-2-ethyl-4-isothiazolin-3-one, 5-chloro-2-tert-octyl-4-isothiazolin-3-one, 4,5-Dichloro-2-n-octyl-4-isothiazolin-3-one, 4,5-dichloro-2-cyclohexyl-4-isothiazolin-3-one, 1,2-benzene And isothiazolin-3-one and so on. These may be used individually by 1 type, and may use 2 or more types together. Among these, Cl-MIT is preferred from the viewpoints of solubility in water, bactericidal performance, and availability. In particular, from the viewpoint of the bactericidal action against bacteria of the genus Legionella, a solid preparation (A) of a halogen-based oxidizing agent containing BCDMH as an active ingredient and a solid preparation of an organic bactericide containing Cl-MIT as an active ingredient are preferred. (B) Combinations.

Regarding the dissolution amount of the solid drug (B) of the organic biocide as an active ingredient, from the viewpoint of obtaining an excellent bactericidal effect, for example, it is effective in the halogen-based oxidizing agent whose active ingredient is Cl-MIT and the solid drug (A). Composition of BCDMH In this case, the concentration (unit: mg/L) of Cl-MIT in the water to be treated is preferably 0.00001 times to 100 times the concentration (unit: mg/L) of the available halogen (in terms of Cl2) of BCDMH in the water to be treated. , more preferably 0.01 times to 30 times, and still more preferably 0.1 times to 1 times. Furthermore, the concentration of Cl-MIT in the water to be treated is preferably 0.0001 mg/L to 5 mg/L, more preferably 0.001 mg/L to 3 mg/L, and still more preferably 0.001 mg/L to 2 mg/L.

The solid chemical (B) includes other well-known compounds used in water treatment agents from the viewpoint of corrosion prevention, scale prevention, and the like, in addition to the above-mentioned organic fungicides. For example, triazole-based compounds, phosphonic acid-based compounds, sulfamic acid-based compounds, ametrine, 2,2-dibromo-3-azopropionamide, bronopol, 2,2-dibromo-2-nitroethanol, zinc pyrithione, thiabendazole, coagulants for low molecular weight polymers of acrylic or maleic acid, and the like. These may be one type or two or more types. However, the addition amount of these compounds is set in the range which does not inhibit the bactericidal action by the solid chemical|medical agent (A) and solid chemical|medical agent (B).

The form of the solid medicine (B) is also not particularly limited like the form of the solid medicine (A), but from the viewpoints of ease of adjustment of the amount of use, ease of handling, and the like, it is preferably in the form of a pill (pellet) or a tablet. (tablet) and other lozenges or granules. From the viewpoint of workability at the time of being accommodated in a container, etc., a tablet is more preferable. The manufacturing method of a tablet is not specifically limited, It can manufacture by a well-known method. Usually, it is produced by press molding using additives such as excipients and binders. By adjusting the type or addition amount of excipients or binders, the dissolution rate of the tablet in the treated water can be improved. line adjustment. As these additives, magnesium stearate, silicon dioxide, magnesium oxide, etc. can be used, for example.

A commercial item can also be used as a solid chemical|medical agent (B) which uses an organic type fungicide as an active ingredient as mentioned above.

Regarding the solid drug (B), the content of the organic fungicides is preferably 1% by mass to 40% by mass, more preferably 2% by mass to 35% by mass, from the viewpoint of an appropriate elution rate of the organic type fungicides, and further More preferably, it is 5 mass % - 30 mass %.

The form of the water-soluble solid drug is not particularly limited, but from the viewpoints of ease of adjustment of the amount of use, ease of handling, and the like, lozenges or granules such as pills or tablets are preferred. Tablets are more preferred from the viewpoints of workability when housed in a container. The manufacturing method of a tablet is not specifically limited, It can manufacture by a well-known method. Usually, it is produced by press molding using additives such as excipients and binders. The dissolution rate of the tablet in the water to be treated can be adjusted by adjusting the type or addition amount of the excipient or the binding agent.

[Water-soluble film]

Examples of the water-soluble film include those derived from synthetic resins or natural products such as polyvinyl alcohol (hereinafter PVA), polyethylene oxide, polyvinyl ether, polyvinylpyrrolidone, pullulan, and cellulose derivatives. Among these, the optimum one can be appropriately used according to the type of the water-soluble solid drug.

For example, when the water-soluble solid chemical is a water treatment agent, it is preferable to use a PVA-based film.

PVA-based film will contain polyvinyl alcohol-based resin (hereinafter, referred to as "PVA-based tree" A film made from raw materials of "fat").

As the PVA-based resin, a resin obtained by saponifying a vinyl ester-based polymer obtained by polymerizing a vinyl ester-based compound can be used. In this embodiment, not only one type of PVA-based resin may be used, but two or more types may be used in combination.

As the vinyl ester compound, vinyl acetate, vinyl formate, vinyl trifluoroacetate, vinyl propionate, vinyl butyrate, vinyl caprate, vinyl laurate, and ethylene tertiary carbonate (versatic acid) can be used ester, vinyl palmitate, vinyl stearate, etc. one or two or more.

The complete dissolution time of the water-soluble film used in the present invention in water at 23° C. (time until a film with a thickness of 50 μm dissolves by 95% or more) is preferably 8 seconds or more and 99 seconds or less, more preferably 12 seconds or more and 99 seconds. Hereinafter, it is further more preferably not less than 57 seconds and not more than 99 seconds.

By setting the complete dissolution time in the above-mentioned range, the active ingredient of the water-soluble solid medicine can be continuously released for a long period of time.

Here, the complete dissolution time in water at 23° C. refers to a value obtained by measuring the time until the film is completely dissolved according to the method described in the later-mentioned Examples as [Water-solubility Evaluation of Film]. When the thickness of the film is different from 50 μm, it is a value converted to the thickness of the film of 50 μm by the following formula (1).

Conversion dissolution time (seconds) = [50/film thickness (μm)] ² × sample dissolution time (seconds) ...... Equation (1)

The disintegration time of the water-soluble film used in the present invention in 23° C. water (time until a film having a thickness of 50 μm is broken) is preferably 40 seconds or less, and more preferably 30 seconds or less.

By setting the disintegration time to the above-mentioned range, the active ingredient of the water-soluble solid medicine can be continuously released for a long period of time.

Here, the disintegration time in water at 23° C. refers to a value obtained by measuring the time until the film is broken according to the method described in the below-mentioned Examples as [Water-solubility Evaluation of Film], and it differs depending on the thickness of the used film. In the case of 50 μm, it is a value converted to a thickness of 50 μm of the film by the following formula (2).

Converted disintegration time (seconds) = [50/film thickness (μm)] ² × sample disintegration time (seconds)... Equation (2)

[water treatment method]

An embodiment of water treatment of the cooling water in the cooling tower using the solid chemical container will be described. In the following embodiments, the partition wall communication path 16 of the storage container functions as an "inflow port", and the partition wall communication path 16, the container communication path 15b, and the container communication path 15c function as "outflow ports".

<The first embodiment>

The first embodiment will be described based on FIGS. 3 and 4 . Arrows in Figure 3 Indicates the flow direction of cooling water.

As shown in FIG. 4( a ), the water-soluble solid medicine S1 to the water-soluble solid medicine S3 packaged by the water-soluble film 17 are accommodated in the storage space 13 . In the first embodiment, the storage container 10 containing the water-soluble solid medicine S1 to the water-soluble solid medicine S3 in the storage space 13 is arranged in the cooling tower so that the falling cooling water hits the top outer wall of the storage container 10 . Inside.

In a counter-flow type (round type) cooling tower, when a sound-absorbing pad is arranged, it is preferable to place it on the sound-absorbing pad. In addition, it may be above a sprinkler plate or the like. Moreover, you may arrange|position in a cooling tower using support members, such as a suspending rope and a bracket.

In addition, in a cross-flow type (square type) cooling tower, a mounting portion for the storage container 10 may be provided in the cooling tower, for example, in the vicinity of a louver in the peripheral portion of the cooling tower, and the storage container 10 may be arranged on the mounting portion. set department. In this aspect, in order to guide the cooling water from the packing material of the cooling tower to the top of the storage container 10, it is preferable to provide, for example, a water conduit or the like.

As shown in FIG. 3 , the cooling water flows into the non-accommodating space 14 through the container communication path 15 a , and flows into the accommodating space 13 from the non-accommodating space 14 through the partition wall communication path 16 .

The cooling water flowing into the storage space 13 first elutes the water-soluble film 17 in which the water-soluble solid drug S1 is packaged in the lowermost portion of the storage space 13 , and then elutes the water-soluble solid drug S1 . The cooling water (eluate) in which the water-soluble solid drug S1 is eluted flows out of the storage container 10 via the container communication path 15b and the container communication path 15c. Through the flow of such cooling water, water-soluble solid chemicals are used to Water treatment of cooling water in cooling towers.

In addition, the amount of cooling water retained in the non-accommodating space varies depending on the size of the non-accommodating space or the inflow and outflow rates of cooling water.

When the water-soluble solid medicine S1 is dissolved, the water-soluble film 17 that is arranged on the top of the water-soluble solid medicine S1 and packed with the water-soluble solid medicine S2 also begins to dissolve from the lower part. During the dissolution process, as shown in Figure 4 (b ), the state in which the film is covered over the horizontal cross section of the storage space 13 , that is, the state in which the gap between the water-soluble solid drug S2 and the storage space 13 is blocked by the water-soluble film 17 . In this state, the water vapor generated by the evaporation of the cooling water flowing into the storage space stays below the film, so that the phenomenon that the water-soluble solid chemical S3 above the film is wetted by water vapor can be suppressed.

In addition, as a factor for the wetting of the water-soluble solid drug, the capillary phenomenon of the water-soluble solid drug itself is also considered. In this embodiment, the water-soluble film 17 remaining between the water-soluble solid drug S1 and the water-soluble solid drug S2 or the water-soluble solid drug The water-soluble film 17 between the water-soluble solid drug S2 and the water-soluble solid drug S3 prevents the suction of cooling water caused by the capillary phenomenon of the water-soluble solid drug, so that the capillary phenomenon of the water-soluble solid drug can be suppressed. wetting.

By suppressing the wetting of the water-soluble solid medicine, the water content of the water-soluble solid medicine can be reduced, and the residual rate of the active ingredient of the water-soluble solid medicine can be increased.

<The second embodiment>

Based on FIG. 4 and FIG. 5 , the water treatment method of the present invention when water treatment of the cooling water in the cooling tower is performed using the solid drug container according to the embodiment of the present invention is described. The second embodiment of the law will be described. Arrows in FIG. 5 indicate the flow direction of cooling water.

As shown in FIG. 4( a ), the water-soluble solid medicine S1 to the water-soluble solid medicine S3 packaged by the water-soluble film 17 are accommodated in the storage space 13 . In the second embodiment, the storage container 10 containing the water-soluble solid medicine S1 to the water-soluble solid medicine S3 in the storage space 13 is floated in the cooling tower so that at least the top outer wall of the storage container 10 is exposed on the water surface The cooling water inside the cooling water pit is on the surface of the cooling water. The cooling water pit may be an upper pit for memorizing the sprayed cooling water, or a lower pit.

In this embodiment, the container needs to be of a material or form that floats on the water surface. In the case where it is difficult to float only by the container, the container can be floated by using a container set using a frame that functions as a "float" in combination.

In order to prevent the container from floating in a wide range, the container may be tied, or a fence or the like that fixes the floating area may be provided.

As shown in FIG. 5 , the cooling water flows into the non-accommodating space 14 through the container communication path 15 b and the container communication path 15 c , and flows into the accommodation space 13 from the non-accommodating space 14 through the partition wall communication path 16 . The water-soluble solid drug S1 in the storage space 13 is dissolved in contact with the cooling water flowing in.

The cooling water flowing into the storage space 13 first elutes the water-soluble film 17 in which the water-soluble solid drug S1 is packaged in the lowermost portion of the storage space 13 , and then elutes the water-soluble solid drug S1 . The cooling water (eluate) in which the water-soluble solid drug S1 is eluted is sent to the storage container via the container communication path 15b and the container communication path 15c 10 outflows. Water treatment of the cooling water in the cooling tower is performed using the water-soluble solid chemical by the flow of the cooling water.

In this embodiment, the container communication path 15a functions as a vent. However, when the falling cooling water hits the top outer wall of the container 10 , the cooling water may also flow into the non-accommodating space 14 from the container communication path 15 a.

In the present embodiment, the wetting of the water-soluble solid drug S3 can be suppressed, the water content of the water-soluble solid drug can be reduced, and the residual of the active ingredient of the water-soluble solid drug can be increased as in the above-mentioned <1st embodiment>. Rate.

<Other implementations>

In the above-described embodiment, the water-soluble solid medicine is packaged by the water-soluble film 17 one tablet at a time, but a plurality of tablets may be aggregated and packaged by the water-soluble film.

In addition, the water-soluble solid medicine and the water-soluble film may be alternately arranged from the bottom in the accommodation space 13 to form a laminated structure of the water-soluble solid medicine and the water-soluble film. In this case, the layer containing the water-soluble solid drug may be one layer or two or more layers, and the layer containing the water-soluble film may be one layer or two or more layers. In addition, the layer containing the water-soluble solid drug may contain one tablet of the water-soluble solid drug, or may contain two or more tablets of the water-soluble solid drug.

In addition, the container can also be covered with granular water-soluble solid pharmaceuticals, covered with a water-soluble film, and then covered with granular water-soluble solid pharmaceuticals on the water-soluble film. Groups of sexual membranes, or multiple groups of strata.

In any embodiment, the water-soluble film is preferably one whose size is larger than the horizontal cross-section of the accommodating space 13 . Thereby, the peripheral edge of the water-soluble film and the inner peripheral surface of the accommodating space 13 By being in contact with each other, it has a function of preventing moisture from infiltrating upward from the gap between the peripheral edge of the water-soluble film and the inner peripheral surface of the housing space 13 .

[Example]

Hereinafter, the present invention will be specifically described by way of examples, but the present invention is not limited to the following examples.

[Evaluation of water solubility of film]

The dissolution time of various commercially available water-soluble films was measured under the following conditions.

<device>

． 1L beaker

. 35mm slide mount (manufactured by FUJIFILM Imaging Systems Co., Ltd.), the size of the window is 35mm x 24mm in width

． Magnetic stirrer

． Stirrer (length 40mm×Φ8mm)

<Sample>

． Various films commercially available as water-soluble films [PVA film (Table 1), water-soluble paper (Table 2), rice paper (oblaat) (Table 3)]

<Test conditions>

． Water temperature: 23℃

. Stirrer speed: 500rpm

． Membrane size relative to water: 35mm×24mm

. The gap between the slide frame and the inner wall of the beaker: 1mm

． Upper window end of slide box: 700mL line of beaker

<Order>

1. Cut the film at a size of 45mm x 45mm, clamp it in a slide frame, and fix it.

2. Prepare 800 mL of pure water at 23°C in a 1 L beaker.

3. Put the stir bar and set the stirrer, and stir at 500rpm.

4. Fix the slide frame holding the membrane with a jig, and put it into the beaker at a right angle with respect to the flow direction.

5. The time until the film ruptures and the time until most (95%) of the film in the frame dissolves were measured, and the former was defined as "disintegration time" and the latter as "complete dissolution time".

In the said Table 1, "drying XRV" means the thing obtained by drying XRV in a 60 degreeC thermostat for 1 day (24 hours).

[Table 2]

The water-soluble film used in the present invention can be appropriately selected according to the type and application of the water-soluble solid drug, and in the method, the complete dissolution time is preferably 8 seconds or more and 99 seconds or less.

The starch-based water-soluble film was not completely dissolved even after 30 minutes. Therefore, when it is used in the present invention, it is assumed that it adheres to the surface of the water-soluble solid drug to promote dissolution, which is not preferable.

[Evaluation test related to water content of water-soluble solid pharmaceuticals and residual ratio of active ingredients]

<Solid drug storage container>

The following samples were accommodated in the solid drug container shown in FIG. 5 .

In addition, as a water-soluble solid medicine, the following were used.

Water-soluble solid drug: A water-soluble solid drug containing 7% by mass of total phosphoric acid and 7% by mass of Cl-MIT

<Sample>

Comparative Example 1 4 tablets of water-soluble solid drug (without film)

Example 1 4 tablets of a water-soluble solid drug (packed in one tablet by a poval film "VF-HP220" (thickness 40 μm) manufactured by Kuraray)

Example 2 4 tablets of water-soluble solid drug (packed one tablet at a time by PVA film "ADVASOL XRV ("XRV" in Table 1)" (thickness 50 μm) manufactured by Sekisui Chemicals)

<Order>

1. Store the sample in a cylindrical container.

2. The storage container containing the sample is installed in the circular cooling tower where the shower is performed.

3. After one week, the sample was taken out, and the residual ratio of the component was investigated based on the dissolved residue.

<Measurement method of moisture content>

The water content of the water-soluble solid drug is measured in the following procedure.

The sample taken out from the cooling tower was placed in a 40°C constant temperature bath and dried until there was no mass change. The moisture content was calculated from the weight loss before and after drying.

<Method for measuring the residual ratio of total phosphoric acid>

The residual ratio of the total phosphoric acid in the water-soluble solid drug was measured in the following procedure.

The dried solid solvent was dissolved in pure water in a manner of 1 g/L, and after heating and decomposing, it was subjected to molybdenum blue absorptiometry using a proportional beam spectrophotometer U-5100 (Hitachi High-tech Science (High-tech) science) Co., Ltd.) to measure.

<Measuring method of Cl-MIT>

The residual ratio of Cl-MIT in the water-soluble solid drug was measured in the following procedure.

The dried solid solvent was dissolved in pure water at 1 g/L, and the measurement was performed using a high performance liquid chromatograph Agilent 1260 (Agilent Technologies Japan, Ltd.).

<Result. Inspection>

Below, the result of the moisture content of the whole tablet which remained after one week is shown.

Comparative Example 1: 66.2%

Example 1: 45.4%

Example 2: 34.1%

As described above, it was confirmed that by using the water-soluble film, the water content of the water-soluble solid drug can be significantly reduced. In particular, when the uppermost water-soluble solid drug was observed, comparable wetting was confirmed in Comparative Example 1, but in Example 2, the moisture content was 5.45%, and wetting was reduced. The reason for this is considered to be that the water-soluble film is in a state of blocking the gap between the water-soluble solid chemical and the storage space, thereby reducing the influence of water vapor. From the comparison between Example 1 and Example 2, it was confirmed that the film of Example 2 was more suitable for the action of blocking the gap between the water-soluble solid drug and the storage space.

Hereinafter, the residual ratio of total phosphoric acid in the entire 4 tablets of the water-soluble solid drug after one week is shown.

Comparative Example 1: 0.5%

Example 1: 23.3%

Example 2: 52.1%

The following shows the Cl-MIT in the whole of the water-soluble solid medicine 4 tablets after one week. the survival rate.

Comparative Example 1: 28.4%

Example 1: 49.8%

Example 2: 66.1%

As described above, the use of the film greatly improves the residual properties of the components. The reason for this is considered to be that the elution of components can be prevented by not promoting wetting.

[Confirmation test for "wetting" by water vapor]

Using the storage container constituting the solid medicine container shown in FIG. 5 , it was confirmed by the following method that wetting by the intrusion of water vapor occurred in the top plate inside the container that did not directly touch water.

<Order>

1. The poval film "VF-HP220" (thickness 40μm) made by Kuraray was glued with an adhesive (Shin-Etsu Chemical Co., Ltd., one-component RTV rubber KE-347). connected to the top surface of the cylindrical container.

2. Set up in a circular cooling tower for two days without putting water-soluble solid chemicals.

<Result. Inspection>

It was confirmed that the water-soluble film completely disappeared at the time point of two days, and the water-soluble film was wetted by the water vapor and dissolved and dropped.

From this result, it was confirmed that in a state like the humidity of 100%, wetting by water vapor (moisture) occurs even if it does not directly touch water.

[Test to confirm the relationship between wetting of film and elution of components]

<Solid drug storage container>

The following samples were accommodated in the solid drug container shown in FIG. 5 .

In addition, as a water-soluble solid medicine, the following were used.

Water-soluble solid drug: water-soluble solid drug containing 7% by mass of benzotriazole

<Sample>

Example 1 4 tablets of a water-soluble solid drug (packed in one tablet by a poval film "VF-HP220" (thickness 40 μm) manufactured by Kuraray)

Example 2 4 tablets of water-soluble solid drug (packed one tablet at a time by PVA film "ADVASOL XRV ("XRV" in Table 1)" (thickness 50 μm) manufactured by Sekisui Chemicals)

<Order>

1. Store the sample in a cylindrical container.

2. The storage container containing the sample is installed in the circular cooling tower where the shower is performed.

3. After one week, the sample was taken out, and the water content of the water-soluble solid drug at the top (the fourth tablet from the bottom) and the residual ratio of benzotriazole were investigated.

<Measurement method of moisture content>

The water content of the water-soluble solid drug is measured in the following procedure.

The sample taken out from the cooling tower was placed in a 40°C constant temperature bath and dried until there was no mass change. The moisture content was calculated from the weight loss before and after drying.

<Measuring method of residual ratio of benzotriazole>

The residual ratio of benzotriazole in the water-soluble solid drug was measured in the following procedure.

The dried solid solvent was dissolved in pure water at 1 g/L, and the measurement was performed using a high performance liquid chromatograph Agilent 1260 (Agilent Technologies Japan, Ltd.).

<Result. Inspection>

Hereinafter, the results of the water content of the water-soluble solid drug and the residual ratio of benzotriazole in the uppermost (the fourth tablet from the bottom) one week later are shown.

Example 1: Moisture content (24.7%), residual ratio of benzotriazole (80.0%)

Example 2: Moisture content (5.4%), residual rate of benzotriazole (100%)

As described above, it was confirmed that the components fell off at a moisture content of 24.7%, and did not fall off at a moisture content of 5.4%.

13‧‧‧Containment space

17‧‧‧Water-soluble film

S1, S2, S3‧‧‧Water-soluble solid drug

Claims (6)

A solid medicine container, which is filled with a water-soluble solid medicine inside a container, and in the solid medicine container, the container has a storage space that can accommodate a plurality of water-soluble solid medicines, and cooling water flows into the solid medicine container. The inflow port of the accommodating space and the outflow port through which the cooling water flows out of the accommodating space include: a container body formed by fitting an upper member and a lower member; a dividing wall dividing the container body into the accommodating space and the A non-accommodating space adjacent to the accommodating space; a dividing wall communication path connects the accommodating space and the non-accommodating space so that cooling water can circulate between the accommodating space and the non-accommodating space, as the an inflow port and the outflow port function; and a container communication path that communicates the inside and the outside of the container so that cooling water can flow between the outside of the container body and the non-container space, and In the accommodating space, a part or the whole of the water-soluble solid medicine is laminated in the vertical direction through a water-soluble film, and at least a part of the water-soluble film is arranged more than the inflow port and the outflow port. on top. The solid medicine container according to claim 1, wherein the water-soluble film is a packaging material for packaging the water-soluble solid medicine. The solid drug container according to claim 1 or claim 2, wherein the water-soluble film is formed by film-forming a raw material containing a polyvinyl alcohol-based resin. The solid drug container according to claim 1 or claim 2, wherein the dissolution time of the water-soluble film in water at 23° C. is 8 seconds or more and 99 seconds or less. The solid medicine container according to claim 1 or claim 2, wherein a gap between the lower end of the partition wall and the bottom surface of the lower member facing the partition wall is a communication path for the partition wall. A water treatment method, which performs water treatment using a solid medicament container, the solid medicament container having a accommodating space capable of accommodating a plurality of water-soluble solid medicaments, an inflow port for allowing water to be cooled to flow into the accommodating space, and a A storage container with an outflow port through which water flows out of the storage space, and the storage container is filled with a water-soluble solid medicine, the storage container includes: a container body, which is formed by fitting an upper member and a lower member; a wall, which divides the container body into an accommodation space and a non-accommodating space adjacent to the accommodation space; divides a wall communication path to communicate the accommodation space and the non-accommodating space to make the accommodation space and the non-accommodating space communicate with each other. Cooling water can flow between the storage spaces, and function as the inflow port and the outflow port; Cooling water can be circulated between the accommodating spaces, and in the accommodating space, a part or all of the water-soluble solid medicament is layered in the vertical direction through the water-soluble film, and at least one part of the water-soluble film is laminated in the vertical direction. department Distributed above the inflow port and the outflow port to perform water treatment using a solid drug container, and the water treatment method uses the cooling water flowing in from the partition wall communication path and the cooling water located in the partition wall. The water-soluble solid medicament S1 at the bottom of the storage space is in contact, and the water-soluble film packaged with the water-soluble solid medicament S1 is eluted, and then the water-soluble solid medicament S1 is eluted. As the water-soluble solid medicament S1 dissolves , a part of the water-soluble film packaged with the water-soluble solid drug S2 disposed directly above the water-soluble solid drug S1 is eluted, and the partially eluted water-soluble film becomes a blockage between the water-soluble solid drug S2 and the water-soluble solid drug S2. The water treatment is performed according to the procedure of the state of the gap of the storage space.

Images